DuoGenic StemCells (ROCO:7607) Gross-Profit-to-Asset % : 10.58% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is DuoGenic StemCells Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. DuoGenic StemCells's annualized Gross Profit for the quarter that ended in Dec. 2024 was NT$6.32 Mil. DuoGenic StemCells's average Total Assets over the quarter that ended in Dec. 2024 was NT$59.72 Mil. Therefore, DuoGenic StemCells's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 10.58%.

DuoGenic StemCells Gross-Profit-to-Asset % Historical Data

The historical data trend for DuoGenic StemCells's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DuoGenic StemCells Gross-Profit-to-Asset % Chart

DuoGenic StemCells Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

-4.29

2.95

5.56

5.34

DuoGenic StemCells Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			5.09	5.70	4.08	2.46	10.58

Competitive Comparison of DuoGenic StemCells's Gross-Profit-to-Asset %

For the Biotechnology subindustry, DuoGenic StemCells's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DuoGenic StemCells's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where DuoGenic StemCells's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

DuoGenic StemCells Gross-Profit-to-Asset % Calculation

DuoGenic StemCells's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	4.103	/	( (94.002	+	59.654)	/ 2 )
	=	4.103	/	76.828
	=	5.34 %

DuoGenic StemCells's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	6.318	/	( (59.785	+	59.654)	/ 2 )
	=	6.318	/	59.7195
	=	10.58 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

DuoGenic StemCells Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of DuoGenic StemCells's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

DuoGenic StemCells Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DuoGenic StemCells Corp (ROCO:7607) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Room R207, Innovation Incubation Center, 145, Xingda Road, South District, Taichung, TWN

Website

https://www.dgsc.com.tw

DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.

DuoGenic StemCells Headlines

No Headlines